Pharmacological treatment options for mast cell activation disease
Open accessThe DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Abstract
Mast cell activation disease (MCAD) is a term referring to a heterogeneous group of disorders characterized by aberrant release of variable subsets of mast cell (MC) mediators together with accumulation of either morphologically altered and immunohistochemically identifiable mutated MCs due to MC proliferation (systemic mastocytosis [SM] and MC leukemia [MCL]) or morphologically ordinary MCs due to decreased apoptosis (MC activation syndrome [MCAS] and well-differentiated SM). Clinical signs and symptoms in MCAD vary depending on disease subtype and result from excessive mediator release by MCs and, in aggressive forms, from organ failure related to MC infiltration. In most cases, treatment of MCAD is directed primarily at controlling the symptoms associated with MC mediator release. In advanced forms, such as aggressive SM and MCL, agents targeting MC proliferation such as kinase inhibitors may be provided. Targeted therapies aimed at blocking mutant protein variants and/or downstream signaling pathways are currently being developed. Other targets, such as specific surface antigens expressed on neoplastic MCs, might be considered for the development of future therapies. Since clinicians are often underprepared to evaluate, diagnose, and effectively treat this clinically heterogeneous disease, we seek to familiarize clinicians with MCAD and review current and future treatment approaches.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Valent, P., Akin, C., Escribano, L., Födinger, M., Hartmann, K., Brockow, K., Castells, M., Sperr, W. R., Kluin‐Nelemans, H. C., Hamdy, N. A. T., et al. (2007) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.2007.01807.x · Cited by 750 · cited 5×
“…X Valent et al. 2007R Escribano et al. 2006R Cromoglicic acid (also known as cromolyn) GPR35; modulation of chloride current X X Soter et al. 1979 Valent et al. 2007R Yang et al. 2010 Edwards et al. 2011 Edwards and Hagberg 2010 Zhang et al. 2016 Escribano et al. 2006R Vitamin C Increased…”
BackgroundInfluentialValent, P., Akin, C., Arock, M., Brockow, K., Butterfield, J. H., Carter, M. C., Castells, M., Escribano, L., Hartmann, K., Lieberman, P., et al. (2012) · International Archives of Allergy and Immunology · doi:10.1159/000328760 · Cited by 654
Self-citationFacci, L., Dal Toso, R., Romanello, S., Buriani, A., Skaper, S. D., & Leon, A. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.8.3376 · Cited by 632
Mast cell activation syndrome: Proposed diagnostic criteria
Akin, C., Valent, P., & Metcalfe, D. D. (2010) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2010.08.035 · Cited by 327
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib
Hantschel, O., Rix, U., Schmidt, U., Bürckstümmer, T., Kneidinger, M., Schütze, G., Colinge, J., Bennett, K. L., Ellmeier, W., Valent, P., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0702654104 · Cited by 284
Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis
Carter, M. C., Robyn, J. A., Bressler, P. B., Walker, J. C., Shapiro, G. G., & Metcalfe, D. D. (2007) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2007.03.032 · Cited by 172 · cited 1×
“…et al. 1998 9 Hennessy et al. 2004 3 Worobec et al. 1996 Thalidomide 16 Gruson et al. 2013 IgE antibody Omalizumab 4 Molderings et al. 2011ba 2 Carter et al. 2007 2 Lieberoth and Thomsen 2015 ß-Sympathomimetics Isoprenaline, terbutaline 5 van Doormaal et al. 1986 Cyclooxygenase…”
BackgroundMolderings, G. J., Brettner, S., Homann, J., & Afrin, L. B. (2011) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-4-10 · Cited by 149 · cited 4×
“…(possibly more effective at twice-daily dosing; personal observation, Table 6 Symptomatic treatment (orally as needed) in MCAD (modified from Molderings et al. 2014) Colitis ⇒ budesonide; for some days, prednisone >20 mg/day Diarrhea⇒ c(h)olestyramine; nystatin; montelukast; 5-HT3 receptor…”
BackgroundInfluentialMast cell activation syndrome: A newly recognized disorder with systemic clinical manifestations
Hamilton, M. J., Hornick, J. L., Akin, C., Castells, M. C., & Greenberger, N. J. (2011) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2011.04.037 · Cited by 132 · cited 2×
“…Oncology, and Transplantation, University of Minnesota, Minneapolis, MN 55455, USA further divided into several subtypes (Valent et al. 2007; Tables 1 and 2), primary MC activation syndrome (MCAS; Table 3; Molderings et al. 2011a; Hamilton et al. 2011; Valent et al. 2012), and MC leukemia (MCL).”
BackgroundTanimoto, A., Ogawa, Y., Oki, C., Kimoto, Y., Nozawa, K., Amano, W., Noji, S., Shiozaki, M., Matsuo, A., Shinozaki, Y., et al. (2015) · Inflammation Research · doi:10.1007/s00011-014-0782-9 · Cited by 111
Familial Occurrence of Systemic Mast Cell Activation Disease
Molderings, G. J., Haenisch, B., Bogdanow, M., Fimmers, R., & Nöthen, M. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076241 · Cited by 94 · cited 1×
“While the prevalence of SM in Europeans ranges between 0.3 and 13 per 100,000 (Haenisch et al. 2012; Cohen et al. 2014; van Doormaal et al. 2013), the prevalence of MCAS may be as high as 17 % (in Germany; Molderings et al. 2013a, b).”
BackgroundInfluentialSelf-citation
Cited by
Pediatric Disorders of Orthostatic Intolerance
Stewart, J. M., Boris, J. R., Chelimsky, G., Fischer, P. R., Fortunato, J. E., Grubb, B. P., Heyer, G. L., Jarjour, I. T., Medow, M. S., Numan, M. T., et al. (2018) · Pediatrics · doi:10.1542/peds.2017-1673 · Cited by 222
Kucharik, A. H., & Chang, C. (2020) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08755-8 · Cited by 122
Diagnosis of mast cell activation syndrome: a global "consensus-2"
Afrin, L. B., Ackerley, M. B., Bluestein, L. S., Brewer, J. H., Brook, J. B., Buchanan, A. D., Cuni, J. R., Davey, W. P., Dempsey, T. T., Dorff, S. R., et al. (2021) · Diagnosis · doi:10.1515/dx-2020-0005 · Cited by 115
Self-citationCharacterization of Mast Cell Activation Syndrome
Afrin, L. B., Self, S., Menk, J., & Lazarchick, J. (2017) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.12.013 · Cited by 101
“There are not yet any biomarkers for predicting effective treatments in the individual or for objectively assessing response; symptom selfassessment guides decisions to further pursue versus cease (at least for a time) trials of yet more of the many therapies shown helpful in various patients with MCAS.(43) Formal qua…”
Self-citationMast Cell Activation Syndrome: A Primer for the Gastroenterologist
Weinstock, L. B., Pace, L. A., Rezaie, A., Afrin, L. B., & Molderings, G. J. (2021) · Digestive Diseases and Sciences · doi:10.1007/s10620-020-06264-9 · Cited by 59
Self-citation
Metadata
- Authors
- Molderings, G. J., Haenisch, B., Brettner, S., Homann, J., Menzen, M., Dumoulin, F. L., Panse, J., Butterfield, J., & Afrin, L. B.
- Venue
- Naunyn-Schmiedeberg's Archives of Pharmacology
- Published
- 2016-04-30
- Volume
- 389
- Issue
- 7
- Pages
- 671-694
- ISSN
- 0028-1298 (ISSN-L)
- 1432-1912
- OpenAlex
- W2345273276
- Cited by
- 79
- References
- 19
- FWCI
- 3.03
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological treatment options for mast cell activation disease. https://app.cochat.ai/papers/10.1007/s00210-016-1247-1
- The paper
- Molderings, G. J., Haenisch, B., Brettner, S., Homann, J., Menzen, M., Dumoulin, F. L., Panse, J., Butterfield, J., & Afrin, L. B. (2016). Pharmacological treatment options for mast cell activation disease. Naunyn-Schmiedeberg's Archives of Pharmacology. https://doi.org/10.1007/s00210-016-1247-1
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.